Another magic cure against cancer. Post No 24.

From here:

ImmunGene and Caliber Biotherapeutics are launching Valor Biotherapeutics as a joint venture. The upstart plans to use technology developed at UCLA to create new cancer therapies that marry antibodies to interferon, with licenses to three mAb-IFN fusion product candidates now in preclinical development. Singhvi, who will lead Valor, is the managing director of Caliber.

The idea driving the startup came from the lab of Professor Sherie Morrison at UCLA, which was licensed to ImmunGene. Morrison's mAb-IFN fusion protein technology is designed to deliver a payload of interferon right to specific tumor sites, similar to the approach taken by other antibody-drug conjugate programs.

Well, the approach to combine mAbs with IFN is in accordance with the modern paradigm, however there are even sexier approaches in terms of investment attraction. In any way we have to wish the authors of the idea good luck in hope that the approach will be helpful in our understanding of what works against cancer and what doesn't.